WuXi XDC Cayman (2268) Fundamentals 2026 — P/E 39.4x, Revenue Analysis | SniperIQ
WuXi XDC Cayman (2268) is a CN-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of HK$69.3B, trading at HK$54.75 on the HKSE. This SniperIQ fundamentals page covers WuXi XDC Cayman's valuation (P/E 39.4x, P/B 5.9x), profitability (net margin 24.9%), revenue (¥5.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is WuXi XDC Cayman's market cap?
WuXi XDC Cayman (2268) has a market capitalization of approximately HK$69.3B, trading at HK$54.75 on the HKSE. Market cap moves with the live share price.
What is WuXi XDC Cayman's P/E ratio?
WuXi XDC Cayman's trailing twelve-month P/E ratio is 39.4x, with a price-to-book (P/B) of 5.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is WuXi XDC Cayman?
WuXi XDC Cayman runs a net profit margin of 24.9%, a gross margin of 36.0%, and an operating margin of 27.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does WuXi XDC Cayman generate?
WuXi XDC Cayman reported revenue of ¥5.9B for fiscal year 2025, with net income of ¥1.5B and earnings per share (EPS) of 1.22. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does WuXi XDC Cayman pay a dividend?
WuXi XDC Cayman does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is WuXi XDC Cayman financially healthy?
WuXi XDC Cayman carries a debt-to-equity ratio of 0.08x and a current ratio of 2.68x, with a market beta of -0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is WuXi XDC Cayman a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For WuXi XDC Cayman (2268) the key facts are: market cap HK$69.3B, P/E 39.4x, revenue ¥5.9B, 52-week range 43.5-85.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track WuXi XDC Cayman's full fundamentals live
Get WuXi XDC Cayman's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.